PRAME and neoplasm: Recent studies have found that PRAME and CTCFL are highly expressed as tumor-specific tumor-associated antigens in ovarian cancer, and a series of TCR-T cells constructed such as PRAME TCR (DSK3PRAME/QLL/A2, 16.3C1RAME/LYV/A24 and 8.10C4PRAME/SPS/B7) and CTCFL TCR (39.2 E12CTCFL/KLH/A2) showed potent and specific anti-tumor responses in vitro and in vivo, showing promise as effective agents for ovarian cancer treatment.118